Pathological Myopic Choroidal Neovascularization

Top drugs studied for this disease

All Approvals Safety alerts Label changes Trial results Research Guidance Withdrawals

CLINICAL_TRIALS trial_result · 2021-06-10
Clinical Trial Update: 601 Versus Ranibizumab in Patients With Pathological Myopic Choroidal Neovascularization (pmCNV) [Phase 2]
Phase 2 clinical trial comparing 601 versus Ranibizumab for pathological myopic choroidal neovascularization is ongoing with unknown status.